Gene Delivery Technologies Market

Market Overview

The global gene delivery technologies market size was valued at USD 3.06 billion in 2021. It is projected to reach USD 11.84 billion by 2030, growing at a CAGR of 16.22% during the forecast period (2022–2030).

The primary use of gene delivery technology is for treating human genetic diseases with gene therapy. Gene therapy is a one-of-a-kind method using the flexible gene to treat any disease. Gene therapy is one of the most promising treatments for various illnesses, including inherited disorders, viral infections, and cancers. The development of cell and gene therapy as treatment options has significantly impacted the pharmaceutical industry. It has also improved treating previously untreatable conditions, such as inherited ones. Approximately 990 companies are actively engaged in developing advanced therapies and their subsequent commercialization. The rapidly shifting landscape of advanced therapies is one of the primary factors driving the growth of the global market for gene delivery technologies.

Market Dynamics

Advancements in Physical Technology and Nanotechnology

Researchers are investing time and energy in studying more complex strategies for physically delivering genes due to nanotechnology and physical technology developments. Some of these methods include electroporation, sonoporation, optoporation, and magnetoporation. These methods quickly gain traction due to their numerous benefits, including their non-toxic design and brief duration. These factors are anticipated to propel the market's product demand, encouraging the operating players to expand organically in sales. Due to these developments, it is anticipated that the market for gene delivery technology will grow.

Growing Investments in New Technologies

The revenue growth is accelerated further by an increase in financing and investment in the sector that supports the investigation, creation, and production of various modes of gene transfer. Viral vectors are currently used in about 70% of gene and cell therapy programs, causing organic revenue growth for biological delivery technologies. The operating players are investing significantly to expand their viral vector production capacity and keep up with the rising demand. Introduction of numerous novel tools for genetic alterations that have made it simpler for the scientific community to outline the complexities of disease at the genomic level has aided in the development of new gene delivery strategies. The market's income is also boosted by ongoing research to develop clinically applicable vectors, including viral and non-viral vectors, to treat debilitating conditions like cancer, Alzheimer's disease, and others with cutting-edge therapies.

Global Gene Delivery Technologies Market Restraint

Adverse Effects and High Cost

Gene therapy may have adverse effects if it enters cells outside of the defective cell in the body. Additionally, there is a concern that reproductive cells may be altered covertly and passed on to subsequent generations. Some gene therapies use inactive viruses to deliver healthy genetic material into ill cells. These viruses can infect the patient receiving treatment. The high cost of the treatment and the rise in drug recalls due to strict regulations in developed nations are likely to restrain the market.

Regional Analysis

The global gene delivery technologies market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

The North American region dominates the global gene delivery technologies market. Several clinical trials are being conducted in the United States to determine the viability of gene therapies as a treatment for cancer, genetic diseases, and HIV/AIDS. In addition, a sizable proportion of significant businesses involved in the production and marketing of gene delivery technologies have their headquarters in the United States. These elements have helped the region to dominate the gene delivery technology market. On the other hand, Asia-Pacific has started to emerge as a formidable competitor in this field. The large population and low operating costs influence drug manufacturers' acceptance of Asia-Pacific as a desirable target market. China is ranked second in the world and is the center for developing cell and gene therapies.

Segmental Analysis

The global gene delivery technologies market is segmented by mode, application, and method.

On the Basis of Mode

Based on mode, the market is divided into biological, chemical, and physical.

The biological vectors segment dominates the market for gene delivery technologies due to the enormous success of Kymriah and Yescarta. Viral vectors have garnered much interest since the first gene therapy products based on them were approved. The exponential growth in the number of viral vector-based R&D programs proves that viral vectors are currently the primary delivery method among end-users. However, several clinical difficulties related to viral systems have encouraged the use of chemical techniques. Chemical gene delivery technologies such as polyethyleneimine (PEI) and polyamidoamine dendrimers are recognized as an alternative to viral gene systems for their capacity to overcome difficulties associated with viral systems.

On the Basis of Applications

Based on application, the market is segmented into gene therapy, cell therapy, vaccines, and research.

The gene therapy segment is the most dominant due to the growing acceptance of gene-based therapies has driven the segment's revenue growth. The increased popularity of gene therapy products worldwide has also accelerated segment growth. The humoral and cellular responses to second-generation DNA vaccines might be more robust, making it simpler to research this disease management strategy. This is expected to accelerate the use of gene-editing tools to create vaccines.

On the Basis of Method

Based on the method, the market is segmented into Ex-vivo, In-vivo, and In-vitro.

The ex vivo method has dominated the market for gene delivery technologies because of its many advantages, including the ability to assess transduction effectiveness before implantation of cells back into the patient and less immunogenic reactions. The fact that it has a high transduction efficiency also contributes to its growing appeal in research settings. In vivo gene therapy poses challenges even though it is the preferred method of gene transduction when highly targeted delivery is required.

Recent Developments

• July 2022- Oxford Biomedica plc (LSE: OXB) ("Oxford Biomedica" or "the Company") announced that it had signed a new three-year Master Services & Development Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca") to facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine. This is an expansion of the initial Master Supply and Development Agreement between the two companies.
• January 2022- Oxford Biomedica plc (LSE: OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced that it had signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. (Nasdaq: CABA) ("Cabaletta Bio"), a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, USA, that focuses on the discovery and development of engineered T cell therapies for patients